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Summary 
 
S-nitrosothiols have a number of potential clinical applications, among which 
their use as antithrombotic agents has been emphasised. This is largely 
because of their well-documented platelet inhibitory effects which show a 
degree of platelet selectivity, although the mechanism of this remains 
undefined. Recent progress in understanding how NO-related signalling is 
delivered into cells from stable S-nitrosothiol compounds has revealed a 
variety of pathways, in particular denitrosation by enzymes located at the cell 
surface, and transport of intact S-nitrosocysteine via the amino acid 
transporter system-L (L-AT). Differences in the role of these pathways in 
platelets and vascular cells may in part explain the reported platelet-selective 
action. In addition, emerging evidence that S-nitrosothiols regulate key targets 
on the exofacial surfaces of cells involved in the thrombotic process (for 
example, protein disulphide isomerase, integrins and tissue factor) suggests 
novel antithrombotic actions which may not even require transmembrane 
delivery of NO. 
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Abbreviations: 
csPDI   Cell surface protein disulphide isomerase 
cyclic GMP  Guanosine 3’:5’-cyclic monophosphate 
cysNO  S-nitrosocysteine 
DAF-FM  4-amino-5-methylamino-2’7’-difluorofluorescein 
GSNO  S-nitrosoglutathione 
L-AT   Amino acid transporter system L 
PDI   Protein disulphide isomerase 
RSNO   S-nitrosothiol 
sGC   Soluble guanylate cyclase 
tPA   Tissue plasminogen activator 
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Introduction 
Cardiovascular disease is the most common cause of death in developed 
countries and arterial thrombosis, following rupture of an atherosclerotic 
plaque, underlies most cases of myocardial infarction and stroke. Thrombus 
formation involves the rapid accumulation of blood platelets and fibrin into an 
occlusive mass within the blood vessel. Platelets adhere to collagen and von 
Willebrand factor exposed in the ruptured plaque, and their activation is 
upregulated by locally generated thrombin, thromboxane and ADP, with 
subsequent surface display of integrin adhesion molecules (principally αIIbβ3) 
in their active conformation, allowing fibrinogen binding and platelet 
aggregation (Mackman, 2008). Thrombin-mediated fibrin formation follows 
triggering of the blood coagulation cascade by exposure (Steffel, Luscher and 
Tanner, 2006) or de-encryption (Bach, 2006) of tissue factor, either located 
within the plaque itself or arriving with the cells accumulated by the thrombus. 
Following these initiating events, thrombin generation is amplified and 
propagated by assembly of coagulation enzyme complexes on the surface of 
activated platelets and other cells (Hoffman and Monroe, 2001) with resulting 
fibrin deposition.  
 
Endothelial dysfunction and loss of nitric oxide bioactivity 
Intravascular platelet activation is evident in ischaemic syndromes affecting 
both the coronary (Gurbel et al. 2004) and cerebral circulations (Badimon and 
Vilahur, 2007), and interactions between activated platelets and the vessel 
wall are thought to contribute not only to the final thrombotic events in 
atherosclerotic disease, but also in the initiation and progression of atheroma 
(Langer and Gawaz, 2008). Failure to control platelets in such circumstances 
is due to endothelial dysfunction, in particular the loss of nitric oxide activity 
(Vanhoutte et al. 2009). Common conditions such as diabetes mellitus, 
hypertension and renal failure are characterised by chronic oxidative stress 
which increases cardiovascular risk, in part by diminishing the availability of 
bioactive nitric oxide (NO) and thus permitting platelets to contribute to 
thrombosis (Freedman and Loscalzo, 2003) . These considerations provide a 
rationale for NO supplementation using donor agents to limit thrombotic risk 
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and a variety of compounds are available for this purpose (Miller and Megson, 
2007). This review will focus on the anti-thrombotic potential of S-nitrosothiols 
(RSNOs), and particular attention will be paid to the mechanism by which 
these compounds deliver NO to platelets and other cells of the vascular 
compartment, since there has been progress in this area which may explain 
reports of selective anti-platelet action from certain RSNO molecules. 
 
S-nitrosothiols  
S-nitrosothiols are a class of compounds produced by the S-nitrosation of 
sulphydryl groups (usually cysteine thiols), and with the general formula R-
SNO. They are sometimes referred to as thionitrites in the older chemical 
literature and their general chemistry and biological properties are 
documented in several review articles (Al-Sa'doni and Ferro, 2000, Hogg, 
2000), as are prospects for their therapeutic use (Richardson and Benjamin, 
2002). Their attractiveness as therapeutic agents is increased by the fact that 
they occur naturally in blood and tissues as endogenous metabolites of NO, 
suggesting that toxicity associated with their use might be low.  
Following the identification of NO as the active component of nitrovasodilator 
drugs (Murad, 1999) and the molecule responsible for the endogenous activity 
known as endothelium derived relaxing factor (Palmer, Ferrige and Moncada, 
1987), it was suggested that physiological RSNO formation might provide a 
means to stabilise and extend the activity of NO (Myers et al. 1990, Stamler et 
al. 1992a). Despite the fact that NO itself is a poor nitrosating agent, plausible 
mechanisms exist for RSNO formation within the biological environment 
(Zhang and Hogg 2005) and these compounds, principally in the form of S-
nitrosoalbumin and S-nitrosohaemoglobin, but also as low molecular weight 
forms (S-nitrosocysteine, s-nitrosocysteinylglycine, S-nitrosoglutathione) are 
found to be naturally occurring in blood and tissues (Giustarini et al. 2003). 
Circulating RSNO concentrations are a matter of dispute, largely through 
differences in methodology (Stamler, 2004), however most reports put them in 
the low nanomolar range.   
RSNOs are simple and cheap to synthesise in the laboratory, an advantage if 
they were to be employed as drugs. Among the suggested clinical uses of 
RSNOs, their potential as anti-thrombotic agents has often been highlighted. 
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There is a substantial literature recording the platelet-inhibitory action of 
RSNOs, and a number of mechanisms have been identified. In addition, a 
smaller number of reports suggest that other components of the haemostatic 
system (for example coagulation and fibrinolysis) may be influenced by these 
agents. 
 
Antiplatelet actions of RSNOs 
Very soon after the identification of NO as an endogenous mediator, it was 
shown that NO inhibited platelet function and that this inhibition coincided with 
stimulation of soluble guanylyl cyclase (sGC) and intra-platelet cyclic GMP 
accumulation (Radomski, Palmer and Moncada, 1987). Nitrovasodilator drugs, 
including various RSNO compounds, had already been shown to suppress 
platelet aggregation via sGC stimulation (Mellion et al. 1983), and further 
reports documented cyclic GMP-mediated inhibition of platelet adhesion, 
aggregation, granule secretion and fibrinogen binding by S-nitrosocysteine 
(cysNO) and S-nitrosoglutathione (GSNO) (Radomski et al. 1992, Lieberman, 
O'Neill and Mendelsohn, 1991, Mendelsohn et al. 1990). Accumulation of the 
second messenger cyclic GMP influences platelet function by activation of 
protein kinase G, with consequent phosphorylation of numerous intracellular 
targets and inhibition of processes including calcium mobilisation, integrin 
αIIbβ3 activation, cytoskeleton rearrangement, granule secretion (Schwarz, 
Walter and Eigenthaler, 2001), activity of thromboxane receptors (Wang et al. 
1998) and phosphoinositide 3-kinase (Pigazzi et al. 1999). It should be noted 
that cyclic GMP-induced platelet inhibition can under some circumstances 
occur independently of NO (Riba et al. 2008), however the physiological 
importance of this mechanism, relative to endothelial NO release, is not yet 
clear. 
Although sGC stimulation probably represents the primary mode of action of 
NO donor agents, including RSNOs, it nevertheless became evident that 
platelet control is also exerted by cyclic GMP-independent mechanisms 
(Gordge, Hothersall and Noronha-Dutra, 1998)(Pawloski, Swaminathan and 
Stamler, 1998, Sogo et al. 2000). A variety of molecular alterations have been 
proposed to mediate this process, including prevention of thromboxane 
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synthesis (Tsikas et al. 1999), nitration of α-actinin (Marcondes et al. 2006) , 
inhibition of the platelet P2Y12 ADP receptor (or, more precisely its cellular 
signalling partners) (Kokkola et al. 2005) and either S-nitrosylation (Walsh et 
al. 2007) or altered phosphorylation (Oberprieler et al. 2007) of the important 
platelet integrin αIIbβ3. There appears to be a requirement for extracellular 
generation of NO to occur before cyclic GMP-independent inhibition of 
calcium signalling and platelet aggregation can be brought about by NO donor 
compounds, including RSNOs (Crane, Rossi and Megson, 2005) . 
 
Other effects of RSNOs on the haemostasis process 
Haemostasis involves the interaction of a variety of components, including 
platelets, vascular cells and proteins of the coagulation and fibrinolytic 
systems, however relatively little work has been published on the direct 
influence of nitric oxide on coagulation and fibrinolysis. Clot formation via 
thrombin-induced polymerisation of fibrin and its subsequent crosslinking by 
factor XIII is accelerated by nitrating, but not non-nitrating oxidants, 
suggesting that nitrosative stress may bring about a pro-thrombotic state 
(Vadseth et al. 2004) , although paradoxically others have reported inhibition 
of fibrin polymerisation by peroxynitrite (a recognised nitrating agent) (Lupidi 
et al. 1999). Conversely, exposure of fibrinogen to the RSNO compound 
GSNO suppresses fibrin polymerisation (i.e an anti-thrombotic effect) through 
what appears to be an allosteric interaction separate from covalent 
modification of the fibrinogen molecule (Geer et al. 2008, Akhter et al. 2002). 
RSNOs may further oppose thrombosis by inhibiting the action of 
transglutaminase enzymes, including coagulation factor XIII (Lai et al. 2001, 
Catani et al. 1998) . The major vascular initiator of fibrinolysis is tissue 
plasminogen activator (tPA), and S-nitrosylation of tPA, as might be brought 
about via transnitrosation from RSNO molecules, confers antiplatelet 
properties on tPA without altering its fibrinolytic action (Stamler et al. 1992b). 
A further intriguing, and possibly crucial aspect of coagulation control by 
RSNOs involves their involvement in switching tissue factor (the main 
physiological trigger for coagulation) into a coagulation inactive form (Ahamed 
et al. 2006). This fits into an emerging paradigm in which tissue factor activity 
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is regulated by a variety of post-translational modifications (Egorina, 
Sovershaev and Osterud, 2008), in particular redox modification of an 
allosteric disulphide bond (Chen et al. 2006). It should be noted, however, that 
the concept of redox regulation of tissue factor is contested (Pendurthi et al. 
2007).  
Thus, via a variety of pathways beyond simple inhibition of platelet function, 
RSNO compounds show potential for anti-thrombotic action.  
 
Anti-thrombotic action of RSNOs  - in vivo studies  
Both low molecular weight and protein forms of RSNO suppress platelet 
activation in animal models (Radomski et al. 1992, Keaney et al. 1993), and 
the anti-platelet action of GSNO coincided with improved tissue survival in a 
rat model of ischaemia/reperfusion injury (Kuo et al. 2004). Novel anti-
thrombotic RSNO molecules with chemical modifications conferring selectivity 
for areas of vascular injury (Miller et al. 2003) or for platelets (Vilahur et al. 
2004) have been developed, and shown to be effective in rabbit and porcine 
models. 
In human patients, GSNO limits platelet activation in severe preeclampsia 
(Lees et al. 1996). In addition, a number of small clinical trials have 
documented a significant anti-thrombotic and/or anti-embolic effect of GSNO 
administration, following surgical procedures such as coronary artery bypass 
grafting (Salas et al. 1998), carotid enderartectomy (Molloy et al. 1998) and 
carotid angioplasty (Kaposzta et al. 2002). An interesting property of GSNO 
identified during human in vivo studies was that it showed a degree of platelet 
selectivity, in that platelet inhibition could be demonstrated with doses of 
GSNO that failed to produce significant vasodilation (de Belder et al. 1994). 
The mechanism of this platelet selective behaviour was not fully defined, but 
the authors speculated that it might relate to different abilities of platelets and 
other vascular cell types to mediate enzymatic release of NO from GSNO. 
 
Delivery of NO signalling by RSNO compounds 
The tissue effects of RSNOs (cyclic GMP generation, vasodilation, platelet 
aggregation inhibition) are not shown by the non-nitrosated parent thiol 
compounds (Mathews and Kerr, 1993), implying that RSNOs must act via 
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transmission of NO-related signals. Nevertheless it was recognised in the 
early 1990s that the rate of spontaneous NO release from different RSNOs 
failed to correlate with their corresponding potencies in bioassay systems, so 
therefore spontaneous NO liberation could not explain the biological actions of 
RSNOs (Mathews and Kerr, 1993, Kowaluk and Fung, 1990) . This lack of 
correlation probably reflects the fact that NO release from RSNOs into 
solution almost always results from catalysis by copper (I) ions, whereas in 
vivo other pathways are involved. The mode of intracellular delivery of NO 
from RSNOs is more complex and RSNOs cannot be viewed as simple “NO 
donors”. 
 
Cellular metabolism of RSNOs 
Cellular metabolism is one possible means of NO delivery and a number of 
studies have documented NO release from RSNOs mediated by intact 
platelets and other cell types (Simon et al. 1993a, Gordge et al. 1998, Liu et al. 
2001, Zeng, Spencer and Hogg, 2001, Cornwell et al. 2003, Shah et al. 2003). 
In addition, RSNOs are substrates for a variety of enzymes including 
glutathione peroxidase (Freedman et al. 1995), a copper (I)-dependent 
enzyme (Gordge et al. 1996),γ-glutamyl transferase (Hogg et al. 1997), 
thioredoxin reductase (Nikitovic and Holmgren, 1996), superoxide dismutase 
(Jourd'heuil et al. 1999), protein disulphide isomerase (Sliskovic, Raturi and 
Mutus, 2005), cytoplasmic metalloprotein (Mani et al. 2006) and GSNO 
reductase (glutathione-dependent formaldehyde reductase, or alcohol 
dehydrogenase 3) (Liu et al. 2001, Liu et al. 2004, ). This latter enzyme 
appears to play a crucial role in regulating nitrosative stress via adjustment of 
intracellular levels of S-nitrosylated proteins (Staab et al. 2009, Foster et al. 
2009), however there is no direct evidence yet for a role in the transfer of NO 
signalling from extracellular RSNOs.  
 
Cell surface protein disulphide isomerase promotes NO delivery across 
the plasma membrane 
Of the enzymes mentioned above, protein disulphide isomerase (PDI) has 
perhaps the best credentials as a mediator of RSNO signalling. PDI was 
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originally characterised as a resident of the endoplasmic reticulum, assisting 
in the correct folding of nascent proteins (Gruber et al. 2006). In recent years 
PDI has been documented at locations outside the ER, including the cell 
surface, cytosol and nucleus (Turano et al. 2002) . Cell surface isomerases, 
including PDI (csPDI), have attracted particular research interest through their 
involvement in infectious disease (Conant andStephens, 2007), HIV entry into 
CD4 positive lymphocytes (Barbouche et al. 2003), platelet aggregation 
(Burgess et al. 2000, Lahav et al. 2003, Jordan et al. 2005,  Robinson et al. 
2006, Manickam et al. 2008), and control of tissue factor activity (Chen et al. 
2006, Versteeg and Ruf, 2007). Studies in mice have confirmed an in vivo role 
for csPDI in both fibrin generation and platelet thrombus formation (Cho et al. 
2008), thus csPDI has a direct bearing on haemostatic regulation.  
A further line of research has shown that csPDI plays an important role in NO 
signalling, specifically the transfer of NO from extracellular membrane-
impermeant RSNOs across the plasma membrane of target cells (Zai et al. 
1999, Ramachandran et al. 2001, Bell, Shah and Gordge, 2007)). The best-
developed model described so far postulates that csPDI denitrosates RSNO 
molecules in the vicinity of the plasma membrane, releasing NO which then 
enters the membrane by virtue of its lipophilicity and combines there with 
oxygen to produce the nitrosating agent N2O3. When this, in turn, nitrosates 
target molecules on the cytoplasmic side of the plasma membrane the goal of 
NO internalisation is achieved (Ramachandran et al. 2001). Our own 
experimental studies have confirmed the role of csPDI in delivery into 
platelets of NO-related signalling from RSNOs , however we also found that 
active csPDI was necessary for signal delivery from donors of nitroxyl (NO-) 
and of NO (Bell, Shah and Gordge, 2007). csPDI-mediated denitrosation 
should not be required for entry of NO, and further work is therefore needed to 
reconcile these results. Redox mechanisms involving the vicinal thiols of the 
csPDI active site underlie the process of RSNO denitrosation (Sliskovic, 
Raturi and Mutus, 2005). The published scheme shows plausibly how a single 
enzyme turnover brings about NO release, but the mechanism of active site 
thiol regeneration, required to continue RSNO signalling, is not yet defined. 
Several studies have documented thiol oxidation within csPDI and loss of 
enzyme activity as a result of the interaction with RSNO (Zai et al. 1999, Root 
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et al. 2004, Shah et al. 2007). Redox regeneration of csPDI may derive from 
both internal sources, via trans-membrane oxidoreductases such as NAD(P)H 
oxidase, and/or from reducing equivalents present in blood plasma. The 
relative importance of these various systems, and the effects of oxidative / 
nitrosative stress on csPDI-mediated processes, need to be known for a full 
understanding of csPDI pathophysiology. 
 
Some RSNO molecules are delivered intact via membrane transporters 
An alternative means of RSNO-mediated signalling is by cellular uptake of an 
intact RSNO molecule via a membrane transporter.  Evidence has emerged 
from a number of different laboratories showing that the low molecular weight 
RSNO compounds S-nitroso-L-cysteine (CysNO) and S-nitrosohomocysteine 
act as substrates for the widely-distributed amino acid transporter system-L 
(L-AT). This mechanism for transmembrane transport of cysNO could explain 
why stereoselective haemodynamic effects are seen following administration 
of L-cysNO and D-cysNO to rats (Davisson et al. 1996), and experimental 
studies carried out in vitro have confirmed its presence in a number of cell 
types including erythrocytes, (Sandmann, Schwedhelm and Tsikas, 2005), 
endothelial cells (Broniowska, Zhang and Hogg, 2006), vascular smooth 
muscle cells (Li and Whorton, 2007, Riego et al. 2009), epithelial cells 
(Granillo et al. 2008), and various transformed cell lines (Zhang et al. 2004, Li 
et al. 2005) although to date there has been no direct demonstration of cysNO 
uptake via L-AT in platelets. In these published studies other forms of RSNOs, 
including GSNO, S-nitroso-cysteinyl-glycine, S-nitroso-N-acetyl-penicillamine 
and S-nitrosoalbumin, failed to be transported via L-AT, nor could they 
mediate NO-related signalling in target cells unless extracellular cysteine was 
supplied.  In the presence of extracellular cysteine, cysNO is formed from the 
inert RSNO by a process of transnitrosation, with subsequent uptake on the L-
AT system and intracellular signal transmission. If only cystine is available, a 
cystine-cysteine shuttle mediated by the Xc- aminoacid transport system can 
import cystine and subsequently release cysteine into the surrounding 
medium following intracellular reduction, thus providing substrate for 
transnitrosation and L-AT mediated uptake of cysNO (Li and Whorton, 2005, 
Zhang and Hogg, 2004). This mechanism has been shown to be relevant for a 
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wide range of signalling events and also for the accumulation of intracellular 
RSNOs. Experiments have generally been performed using relatively high 
RSNO concentrations (20 μΜ upwards) and endpoints measured after RSNO 
exposure for at least 15 minutes. An interesting feature to emerge from these 
studies is that in general, cellular effects mediated by cysNO / L-AT are 
insensitive to the presence in the extracellular medium of NO scavengers, 
such as oxyhaemoglobin, thus excluding NO release from the mechanism 
(Zhang and Hogg, 2004, Zhu et al. 2008). An exception is when cysNO-
mediated stimulation of sGC is considered – this process is inhibited by 
oxyhaemoglobin, but only because intracellular reduction of cysNO to NO is 
required before a cyclic GMP response can occur (Riego et al. 2009). 
 
Different modes of RSNO delivery may explain their selective 
antithrombotic action  
RSNOs are potent platelet inhibitors (see above) but it is not yet clear that 
their antiplatelet actions require prior conversion of RSNO to cysNO and 
transport into the platelet via the L-AT system. In vitro aggregation of washed 
platelet suspensions is inhibited by a range of RSNO molecules without need 
for addition to the surrounding medium of cysteine or cystine (Radomski et al. 
1992, Gordge, Hothersall and Noronha-Dutra, 1998, Mathews and Kerr, 1993, 
Simon et al. 1993b), and unlike L-AT mediated actions, platelet inhibition 
(both cyclic GMP-dependent and –independent) is inhibited by haemoglobin 
(Radomski et al. 1992, Crane, Rossi and Megson, 2005, Megson et al. 2000), 
implying that release of free NO must occur as part of the process. For protein 
RSNOs, such as S-nitrosoalbumin, to inhibit platelet aggregation, there does 
appear to be a requirement for prior transnitrosation to a low molecular weight 
thiol for the anti-platelet action to be realised, however this function can be 
fulfilled as efficiently by glutathione or cysteinyl-glycine as by cysteine (Crane 
et al. 2002). Studies using washed platelets have not included measurement 
of cysteine concentrations in the surrounding medium, and it is therefore 
possible that cysteine released by the platelets themselves mediates NO 
signal transfer via L-AT, however this seems unlikely since the anti-platelet 
action of GSNO, for example, is evident at lower concentrations (10 μM or 
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less) and within a more rapid timeframe (< 2 minutes) than effects reported for 
L-AT-mediated signalling. Furthermore, if the inhibitory action of GSNO 
depended upon cysNO / L-AT then it might be expected to be more potent in 
platelet rich plasma (where plasma cysteine/cystine is available) than in 
washed platelet suspensions, whereas in fact the reverse is true (Radomski et 
al. 1992).  In a recent publication addressing the possible modes of intra-
platelet transport of NO, neither cyclic GMP accumulation nor DAF-FM 
fluorescence in response to GSNO was significantly inhibited by the L-AT 
inhibitors BCH or L-leucine (Bell, Shah and Gordge, 2007). Therefore, despite 
a wealth of evidence for the importance of the cysNO / L-AT system in 
endothelial and smooth muscle cells of the vascular wall, platelets appear to 
respond to RSNOs in a different way (figure 1). If this anomalous behaviour of 
platelets, compared with other vascular cells, can be confirmed then a 
possible explanation for the reported platelet-selectivity of GSNO is suggested 
(de Belder et al. 1994), since, at low concentrations, this molecule may have 
access to a direct anti-thrombotic action on platelets that is not available to 
endothelial or smooth muscle cells.  
The susceptibility of GSNO’s anti-platelet action to NO scavenging by 
haemoglobin suggests instead that it undergoes platelet-mediated metabolism, 
either by a (so far uncharacterised) copper-dependent surface enzyme  
(Gordge et al. 1995, Gordge et al. 1996) , or by csPDI which is known to be 
present on platelets (Essex, Chen and Swiatkowska, 1995) and capable of 
releasing NO (Root, Sliskovic and Mutus, 2004). If differences exist in csPDI 
expression between platelets and vascular cells, then it might be possible to 
exploit this to provide selective anti-thrombotic action. The inhibition of platelet 
csPDI which results from interaction with RSNO molecules (Shah et al. 2007) 
is potentially a major antithrombotic mechanism, since there is abundant 
evidence that active csPDI is required for platelets to function efficiently during 
haemostasis (Essex, 2004).  
Another possible reason why RSNOs might mediate selective anti-thrombotic 
effects is that a number of functionally important nitrosation targets exist on 
the external surface of platelets. These include csPDI itself but also the 
adhesion molecules glycoprotein 1b (Burgess et al. 2000) and integrin αIIbβ3  
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(Walsh et al. 2007, Yan and Smith, 2000). Allosteric disulphides on tissue 
factor and other haemostatically active extracellular proteins (Chen and Hogg, 
2006) present further possible targets for alteration by plasma RSNOs. Thus 
although RSNO-mediated signalling to the vessel wall via intracellular thiol 
modification requires processing via the cysNO / L-AT system, the ability of 
GSNO (and other RSNOs) to modify important exofacial targets on platelet 
and other cells may confer selective anti-thrombotic action (figure 2).  
 
Conclusion 
Possible mechanisms for selective anti-thrombotic action of RSNOs may be 
summarised as: 
1. Differences between platelets and cells of the vascular wall in 
expression of RSNO metabolising enzymes, such as csPDI, and / or 
dependence on csPDI for signal transmission.  
2. Differences between platelets and cells of the vascular wall in 
expression of the L-AT system, or dependence on cysNO /  L-AT as a 
mode of NO delivery. 
3. A heightened role in platelets, compared with cells of the vascular wall, 
for modification of target proteins on the external surface of the plasma 
membrane, thus allowing at least partial inhibitory effects to be 
achieved without need for intracellular delivery of NO. 
4. RSNO-mediated regulation of blood coagulation, in particular tissue 
factor exposed at sites of vessel injury or on circulating monocytes or 
platelet microparticles. This might be either a direct effect or secondary 
to csPDI modification.  
 
There are few experimental data directly comparing these different 
mechanisms between platelets and cells of the vascular wall, so it is difficult to 
grade the mechanisms in order of importance. Nevertheless, the evidence 
currently available suggests a scenario in which denitrosating enzymes on 
platelets permit low concentrations of RSNO to mediate anti-thrombotic NO 
signalling, whereas higher concentrations of RSNO are required for 
vasodilatory signalling via the cysNO / L-AT mechanism. A further impeding 
factor may be the need for RSNO to cross the endothelial monolayer to gain 
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entry into vascular smooth muscle, both of which steps involve cysNO / L-AT. 
At present these ideas remain speculative, however they do suggest lines of 
enquiry that might help define and realise the anti-thrombotic potential of 
RSNO compounds. 
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Figure Legends 
 
 
Figure 1 
Different modes of NO delivery from RSNOs. Cells of the vascular wall import 
NO principally via uptake of cysNO on the L-AT amino acid transporter 
system, following an extracellular process of transnitrosation from RSNO to 
cysteine. A cystine-cysteine shuttle mediated by the Xc- transporter may act 
as a supply of extracellular reduced cysteine. In contrast NO delivery into 
platelets relies on the activity of cell surface denitrosating enzymes, such as 
csPDI. This scheme indicates the main routes of NO uptake, but does not 
exclude the possibility that alternative or additional routes are available for 
each cell type. 
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Figure 2. 
Cell surface targets for the antithrombotic action of RSNOs. Inhibition of the 
thrombotic process may be mediated without the need for intracellular NO 
entry, by inactivation of platelet surface adhesion molecules and/or of tissue 
factor exposed on the surface of the damaged vascular wall, on activated 
monocytes or circulating microparticles. These modifications occur indirectly 
via RSNO-induced inhibition of csPDI, and also possibly via direct 
transnitrosation of the target molecule. 
 
 
